Among postmenopausal women with
osteoporosis at risk of fracture, daily injection of the
drug abaloparatide for 18 months significantly reduced the risk of new vertebral and nonvertebral fractures
compared with placebo, according to a study appearing in the August 16 issue of JAMA.
Letrozole has side effects, and the women who took it for a prolonged period as part of the study suffered more bone pain, fractures and the onset of
osteoporosis compared with the women who didn't get the
drug.